This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.
Upon determination of eligibility, all patients will be receive: * Irinotecan + Carboplatin + Imatinib
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Overall response rate
Response duration
Time to progression
Overall toxicity
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.